(Q42518016)

1 November 2017

title

A pilot study of the long-term effects of acipimox in polycystic ovarian syndrome (English)

1 reference

1 November 2017

Ciampelli M

1

1 reference

1 November 2017

Leoni F

2

1 reference

1 November 2017

Lattanzi F

3

1 reference

1 November 2017

Guido M

4

1 reference

1 November 2017

Apa R

5

1 reference

1 November 2017

Lanzone A

6

1 reference

1 November 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

1 November 2017

1 reference

1 November 2017

volume

17

1 reference

1 November 2017

issue

3

1 reference

1 November 2017

page(s)

647-653

1 reference

Assessment of insulin sensitivity in vivo

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Insulin and polycystic ovary syndrome: a new look at an old subject.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Effect of fatty acids on glucose production and utilization in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: effects of acipimox

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Effect of differences in glucose tolerance on insulin's ability to regulate carbohydrate and free fatty acid metabolism in obese individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Effects of nonesterified fatty acids on glucose metabolism after glucose ingestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Suppression of non-esterified fatty acids to treat type A insulin resistance syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Evidence of a disturbance of the hypothalamic-pituitary-adrenal axis in polycystic ovary syndrome: effect of naloxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Effects of body fat distribution on regional lipolysis in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Genotyping Steroid 21-Hydroxylase Deficiency: Hormonal Reference Data*

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Role of abnormal free fatty acid metabolism in the development of non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.3.647

21 January 2018

Identifiers

DOI

10.1093/HUMREP/17.3.647

1 reference

1 November 2017

1 reference